Optimization of Ovarian Stimulation for Women with Endometrial Atypical Hyperplasia and Endometrial Cancer by Combination of Traditional Chinese and Western Medicine

Research and Development of Fertility Preserving Technology for Women with Gynecological Tumour

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2100004271

Enrollment

Unknown

Registered

2021-01-15

Start date

2021-01-18

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer and Endometrial Atypical Hyperplasia

Interventions

Effect of combination of Traditional Chinese and Western Medicine on In vitro fertilization and embryo transfer for fertility preservation women with endometrial atypical hyperplasia and endometrial c

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Aged <= 40 years, women with a strong desire for childbearing; (2) Women with endometrial atypical hyperplasia and endometrial cancer obtain remission after fertility sparing therapy; (3) FIGO (2018 edition) staging: endometrial cancer IAG1-IAG2 Endometrial atypical hyperplasia; (4) Imaging examination confirmed that the cancer was localized in the endometrium; (5) Both estrogen receptor and progesterone receptor (ER, PR) were positive; (6) Peripheral blood CA125 was normal; (7) No severe fertility barriers after assessment of fertility ability; (8) Women sign informed consent and have better follow-up conditions.

Exclusion criteria

Exclusion criteria: (1) Women with serious diseases or severe impairment of liver and kidney function; (2) Women with endometrioid adenocarcinoma whose pathological stage or grade is higher than that of stage Ia and G2, or those with deep myometrial invasion, cervical invasion, or metastasized to pelvic and abdominal cavity; (3) Women with other types of endometrial cancer or other malignant tumors of the reproductive system; (4) Chronic diseases which are not suitable for pregnancy.

Design outcomes

Primary

Measure	Time frame
Live birth rate;	—

Secondary

Measure	Time frame
Clinical pregnancy rate;Ovarian reserve;	—

Countries

China

Contacts

Public ContactQun Lu

Peking University People's Hospital

luqun1023@sina.com+86 13164242297

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026